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Abstract
Background: Melanoma is the most aggressive and deadly form of skin cancer with increasing case numbers
worldwide. The development of inhibitors targeting mutated BRAF (found in around 60% of melanoma patients)
has markedly improved overall survival of patients with late-stage tumors, even more so when combined with MEK
inhibitors targeting the same signaling pathway. However, invariably patients become resistant to this targeted
therapy resulting in rapid progression with treatment-refractory disease. The purpose of this study was the
identification of new kinase inhibitors that do not lead to the development of resistance in combination with BRAF
inhibitors (BRAFi), or that could be of clinical benefit as a 2nd line treatment for late-stage melanoma patients that
have already developed resistance.
Methods: We have screened a 274-compound kinase inhibitor library in 3 BRAF mutant melanoma cell lines (each
one sensitive or made resistant to 2 distinct BRAFi). The screening results were validated by dose-response studies
and confirmed the killing efficacies of many kinase inhibitors. Two different tools were applied to investigate and
quantify potential synergistic effects of drug combinations: the Chou-Talalay method and the Synergyfinder
application. In order to exclude that resistance to the new treatments might occur at later time points, synergistic
combinations were administered to fluorescently labelled parental and resistant cells over a period of > 10 weeks.
Results: Eight inhibitors targeting Wee1, Checkpoint kinase 1/2, Aurora kinase, MEK, Polo-like kinase, PI3K and Focal
adhesion kinase killed melanoma cells synergistically when combined with a BRAFi. Additionally, combination of a
Wee1 and Chk inhibitor showed synergistic killing effects not only on sensitive cell lines, but also on intrinsically
BRAFi- and treatment induced-resistant melanoma cells. First in vivo studies confirmed these observations.
Interestingly, continuous treatment with several of these drugs, alone or in combination, did not lead to emergence
of resistance.
Conclusions: Here, we have identified new, previously unexplored (in the framework of BRAFi resistance) inhibitors
that have an effect not only on sensitive but also on BRAFi-resistant cells. These promising combinations together
with the new immunotherapies could be an important step towards improved 1st and 2nd line treatments for
late-stage melanoma patients.
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Background
Melanoma is a very aggressive form of skin cancer where
advanced stages are generally associated with poor pa-
tient survival [1]. Together with lung cancer, melanoma
is characterized by the highest number of somatic muta-
tions, mostly due to the exposure to environmental muta-
gens such as tobacco smoke or UV rays, respectively [2].
Mutations in the Ser/Thr-kinase BRAF (especially the
V600E mutation) are responsible for abnormal MAPK
pathway signaling in more than 50% of melanoma pa-
tients. The development of a targeted therapy against this
constitutively active BRAF has revolutionized the treat-
ment of late-stage melanoma patients. In 2011, two BRAF
inhibitors (Vemurafenib and Dabrafenib) were approved
by the Food and Drug Administration for clinical use in
late-stage patients [3, 4]. However, the emergence of rapid
drug resistance in most patients challenges the overall
positive response rates for these inhibitors. Therefore, a
combination therapy targeting BRAF together with MEK,
a downstream kinase in the same signaling pathway (by
using Trametinib or Cobimetinib) was approved in 2015
for stage III and IV melanoma patients [5] increasing the
overall survival from approximatively 15months for single
treatments to 25months and delaying the onset of drug
resistance [6, 7]. Nevertheless, drug resistance also occurs
after combined BRAF/MEK inhibition causing unresolved
clinical issues. A number of mechanisms conferring kinase
inhibitor resistance have been described [8], many of
which converge on a process termed “phenotype switch-
ing”, whereby melanoma cells escape inhibition by revers-
ibly adapting proliferation rates, by metabolic re-wiring,
and by differentiation/de-differentiation processes.
Recently, immunotherapy with immune checkpoint in-
hibitors has become a promising 2nd line treatment for
resistant patients or a 1st line treatment for BRAF
wild-type (wt) patients, however, response rates are not
exceeding 30% and treatment can be accompanied by se-
vere side effects [9, 10].
Melanoma are very heterogeneous tumors [11, 12] and
individual cells can gain additional mutations when
evolving from primary lesions to metastasis or when
subjected to therapy, which can be a major limitation to
durable therapeutic responses. Therefore, the identifica-
tion of novel drugs or drug combinations to delay or
completely abolish the onset of resistance by targeting
alternative pathways, proteins involved in cell cycle pro-
gression or the DNA damage response (DDR) pathway
[13, 14], remains a clinically very important task and a
number of new drugs are currently in clinical trials
(reviewed in [15]).
Most intrinsic or acquired mutations (under treatment
pressure) inevitably lead to the reactivation of the
MAPK signaling pathway or activation of the PI3K/Akt
pathways, all driving proliferation of cancer cells. As
most signaling pathways involve kinases, we screened a
kinase inhibitor library in parental melanoma cell lines
alongside their corresponding Vemurafenib- and
Dabrafenib-resistant sublines in order to identify new
potential targets. We determined potent combinations of
kinase inhibitors, which showed long-lasting synergistic
effects in the treated cells.
Methods
Cell lines and cell culture
The melanoma cell line A375 was obtained from ATCC,
IGR37 and IGR39 melanoma cells were purchased from
DSMZ and 501Mel melanoma cells were acquired from
Dr. Ruth Halaban (Dermatology department, Yale School
of Medicine, USA). Primary BRAF mut melanoma M45
cells were freshly isolated from a patient muscle metas-
tasis at the Dermatology department, Technical Univer-
sity Dresden in Germany. The chopped tumor was
incubated in HBBS (w/o Ca2+ and Mg2+) containing
0.05% collagenase, 0.1% hyaluronidase, 1.25 U/ml dispase
20 mM HEPES, 100 g/ml gentamycin; 100 U/ml penicil-
lin and 100 g/ml streptomycin, for 60 min at 37 °C. After
centrifugation, cell pellets were washed in HBSS/20 mM
HEPES and maintained in RPMI + 10% FCS. The use of
patient material for biochemical analysis was approved
by the ethics committee of the TU-Dresden (EK
65032013) and informed consent was obtained from the
patient. The drug-resistant counterparts of A375, IGR37
and 501Mel cells (-XP: Vemurafenib (PLX4032)-resistant,
-GP: Dabrafenib (GSK2118436)-resistant) were produced
as described before [16]: Drug-resistant melanoma cell
pools were generated from parental A375, IGR37, and
501Mel cells by long-term culturing under continuous
presence of 5 μM Vemurafenib (PLX4032) or 100 nM
Dabrafenib (GSK2118436). Inhibitor-containing media
were exchanged three times a week. The parental A375
and resistant -XP and -GP derivatives were stably
transduced with the near-infrared fluorescent protein
(iRFP) using the LV-iRFP-P2A-Puro lentiviral particles
(Imanis Life Sciences) as described in [17]. All cells were
maintained in RPMI-1640 containing GlutaMAX™
(GIBCO) and supplemented with 10% FCS (GIBCO),
50 μg/ml penicillin (LONZA) and 100 μg/ml streptomycin
(LONZA). The BRAFi-resistant cell lines and the
iRFP-transduced cells were maintained under continuous
presence of the inhibitor (Vemurafenib or Dabrafenib,
Selleck Chemicals) and the selection antibiotic (Puro-
mycin, Invivogen) respectively. Normal human epidermal
melanocytes NHEM (PromoCell) were maintained in
serum- and PMA-free MGM-M2 medium. Normal
Human Dermal Fibroblasts, NHDF (PromoCell) were
grown in DMEM containing GlutaMAX™ (GIBCO) and
supplemented with 10% FCS (GIBCO), 50 μg/ml penicillin
(LONZA) and 100 μg/ml streptomycin (LONZA). All cells
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were cultured in a humidified atmosphere with 5% CO2
supply and were regularly PCR-tested to be mycoplasma-
negative.
Kinase inhibitor library
The kinase inhibitor library, composed of 274 com-
pounds dissolved in DMSO in a stock concentration of
10 mM, was purchased from Selleck Chemicals (Hous-
ton, USA). A375, IGR37 and 501Mel parental and
BRAFi-resistant cells were seeded at a density of 0.5 ×
104 cells/well in 96-well black μclear plates (Greiner) in
the presence of 1 or 10 μM inhibitor. After 72 h of treat-
ment, cell viability was assessed using the PrestoBlue
Cell Viability Reagent (ThermoFisher Scientific). Mea-
surements were performed with the CLARIOstar Mono-
chromator microplate reader (BMG Labtech).
Dose-response curves and determination of IC50 values
All inhibitors used in this study were purchased from
Selleck Chemicals (Houston, USA). They were dissolved
in DMSO to a stock concentration of 10 mM according
to the manufacturer’s instructions and stored at − 80 °C.
Briefly, A375, IGR37 and 501Mel parental and their
BRAFi-resistant -XP and-GP derivatives were seeded at a
density of 0.5 × 104 cells/well in 96-well black μclear
plates (Greiner). Eight different dilutions (in a 3-fold di-
lution series) of each inhibitor (ranging from 0.05 to
10,000 nM) were assayed in technical triplicates for 72 h
in each experiment. Cell viability was measured with the
PrestoBlue Cell Viability Reagent (ThermoFisher Scien-
tific) on a CLARIOstar Monochromator microplate
reader (BMG Labtech). Using the GraphPad Prism v5.04
software, the half-maximal inhibitor concentration
values (IC50) were determined from the curve using the
nonlinear log (inhibitor) vs response-variable slope (four
parameters) equation. IC50 values were only determined
for compounds which inhibited growth by more than
50%. In addition, the IC50 values were only considered if
the software gave unambiguous results and the R2 value
was above 0.92. The IC50’s were determined for 3 bio-
logical replicates and are listed with their standard
deviations.
Synergy determination with the Chou-Talalay method
The Chou-Talalay method [18] to determine possible
synergistic effects of selected kinase inhibitor combina-
tions was used as described in [19]. A375, IGR37 and
501Mel parental and BRAFi-resistant cells were seeded
at a density of 0.5 × 104 cells/well in 96-well black μclear
plates (Greiner). Cells were treated with either single in-
hibitors or combinations thereof at indicated amounts in
technical triplicates. The amounts were pre-determined
from each inhibitor’s IC50 value and inhibitors were
assayed in a defined dilution series and at constant ratio
when combined. Cell viability was measured after 72 h
of treatment, with the PrestoBlue Cell Viability Reagent
(ThermoFisher Scientific) on a CLARIOstar reader
(BMG Labtech). Combination Index (CI) values showing
either synergy (< 1) or antagonism (> 1) were calculated
with the CompuSyn software (ComboSyn, Inc).
Synergy determination with the SynergyFinder method
A375 parental and the BRAFi-resistant -XP and-GP de-
rivatives were seeded at a density of 0.5 × 104 cells/well
in 96-well black μclear plates (Greiner) and were further
treated as described above. Synergy scoring was deter-
mined using the “inhibition readout” (calculated as “100
- Cell Viability”) on the online SynergyFinder software
(https://synergyfinder.fimm.fi) [20] and implementing
the ZIP calculation method [21].
Apoptosis assays
Apoptosis assays were performed by monitoring the
caspase-3 activity through cleavage of the Ac-DEVD-AFC
peptide (AlfaAesar) and the release of fluorogenic AFC (=
7-Amino-4-trifluoromethylcoumarin) in solution. Briefly,
A375 parental and BRAFi-resistant cells were seeded at a
density of 0.5 × 104 cells/well in 96-well black μclear plates
(Greiner). Cells were left untreated or were treated with
200 μM Etoposide (Sigma-Aldrich), used as a positive con-
trol of apoptosis, or MK-1775 and AZD7762 inhibitors ei-
ther single or in combination at the indicated amounts
and in technical triplicates. After 24 h of inhibitor treat-
ment, cells were lysed for 30min at 37 °C with 3x ReLy
Buffer (150mM Tris (pH 7.4), 300mM NaCl, 30% gly-
cerol, 1% Triton-X, 0.3% CHAPS, 6 mM EDTA (pH 8.0),
6 mM DTT, 75 μM Ac-DEVD-AFC) and free AFC was
quantified on a CLARIOstar reader (BMG Labtech). To
ensure specificity of the assay, caspase-3 mediated cleav-
age of the Ac-DEVD-AFC peptide was in parallel blocked
by addition of the potent Ac-DEVD-CHO caspase-3 in-
hibitor (AlfaAesar) at a concentration of 25 μM. Statistical
significance was determined with one-way repeated mea-
sures ANOVA followed by Dunnett’s post-test using the
Graphpad Prism Software.
Long-term inhibitor treatment
A375 parental and BRAFi-resistant cells, virally trans-
duced with the near-infrared fluorescent protein (iRFP)
were seeded at a density of 2500 cells/well in a 24-well
plate (Greiner) in at least technical triplicates. Inhibitors,
single or in combination, were added at the indicated
amounts and replenished every 72 h for a duration of 76
days. To assess whether any remaining cells have be-
come resistant to the treatment and would re-emerge,
the drugs were removed and the cells underwent “drug
holidays” for an additional 21 days. During the long-term
treatment, cell proliferation was monitored bi-weekly on
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a LI-COR Odyssey Infrared Imaging System (LI-COR
Biosciences). Fluorescence intensity was quantified with
the Image Studio™ Lite software (LI-COR Biosciences).
Western blots
Cells were seeded at a density of 105 cells/well in 24-well
plates (Greiner). 24 h post seeding, cells were treated with
inhibitors at indicated amounts for 3 h and/or 24 h. West-
ern blot analysis was performed as described before [22].
The following primary antibodies were used: anti-phos-
pho-CHK1 (Ser317) (Cell Signalling Technology, 1:1000),
anti-CHK1 (Cell Signalling Technology, 1:1000),
anti-phospho-cdc2 (Tyr15) (Cell Signalling Technology,
1:1000), anti-cdc2 (Cell Signalling Technology, 1:1000),
anti-PARP (Cell Signalling Technology, 1:1000), anti-clea-
ved-PARP (Cell Signalling Technology, 1:1000), anti-phos-
pho-Erk (Tyr202/Tyr204) (Cell Signalling Technology,
1:2000), anti-Erk1/2 (Santa Cruz, Erk1 = 1:1000, Erk2 =
1:2000), anti-phospho-Akt (Ser473) (Cell Signalling Tech-
nology, 1:1500), anti-Akt1/2 (Santa Cruz, 1:1000),
anti-Vinculin (Abcam, 1:1000) and anti-Tubulin (Santa
Cruz, 1:5000). HRP-labeled secondary antibodies were
purchased from Cell Signaling Technology (Boston, MA).
In vivo assays
NOD scid gamma (NSG) mice were bred in-house and ex-
periments were performed according to all applicable laws
and regulations, after receiving approval by the institution’s
animal experimentation ethics committee and the veterinar-
ian service of the Ministry of Agriculture (Permit Number:
18-MDM-01). Single parental sensitive A375 cells (0.5 × 106
cells) and Vemurafenib-resistant A375-XP cells (2 × 106
cells) were resuspended in 100 μL of 1:1 mixed serum-free
medium and matrigel (BD Biosciences) and injected sub-
cutaneously in 6–8week-old mice. At day 14, mice (n = 10
mice/group for A375 cells and n = 5 mice/group for
A375-XP cells) had tumors with volumes of approximately
150mm3. Daily treatment was started for 8 consecutive days
with vehicle, 40mg/kg MK-1775 (formulated in 0.5% meth-
ylcellulose) given by oral gavage, 25mg/kg AZD7762 (for-
mulated in 11.3% 2-hydroxypropyl-β-cyclodextrin in 0.9%
sterile saline) given by daily intraperitoneal injection, or the
combination of MK-1775 and AZD7762. Control mice re-
ceived the respective vehicle by oral gavage and intraperito-
neal injection. Tumor growth was followed and tumor
volumes were calculated by the formula 0.5236 × length ×
width × height. Statistical analysis was done using a
two-way ANOVA followed by post-hoc Tukey’s multiple
comparison tests.
Results
Kinase inhibitor library screening
In order to identify new kinases that could act as potential
therapeutic targets to overcome BRAF inhibitor resistance,
we screened a kinase inhibitor library of 274 compounds in
3 different melanoma cell lines that carry a mutated BRAF
gene and are wild-type for NRAS: A375 cells with homozy-
gous BRAF V600E and IGR37 and 501Mel cells heterozy-
gous for BRAF V600E. All 3 cell lines were sensitive to the
BRAF inhibitors Vemurafenib and Dabrafenib (Table 1 and
[16]). Matching cells resistant to these 2 BRAF inhibitors
had previously been generated and characterized in our lab
[16]. The parental and 2 corresponding BRAFi-resistant cell
lines were incubated for 72 h with 2 different concentra-
tions (1 and 10 μM) of the individual drugs and cell viability
was assessed (Additional file 1: Table S1). For further
testing, we chose 40 inhibitors that either (i) had effects at
low (1 μM) concentrations (e.g. Dinaciclib (CDKi), PIK-75
(PI3Ki, DNA-PKi), Trametinib (MEKi)), (ii) showed
differences between parental and resistant cells (e.g.
NVP-BHG712 (VEGFRi, Srci, Rafi, Bcr-Abli), Temsiroli-
mus (mTORi), Sorafenib (VEGFRi, PDGFRi, Rafi)), (iii)
had been described in literature to affect melanoma cells
(e.g. MK-1775 (Wee1i), AZD7762 (Chki), Danusertib
(AURKi, FGFRi, Bcr-Abli, c-RETi, Srci)) or iv) had com-
parable effects in at least 2 of the 3 different cell lines (e.g.
ON-01910/Rigosertib (Plki), KX2–391 (Srci)). An over-
view of the study design and the selection of compounds
for next round evaluations and combinatorial testing in
short- and long-term experiments are shown in Fig. 1 and
Table 1 respectively.
Dose-response assays of 40 selected inhibitors on
parental and resistant melanoma cells
To validate the effects of the 40 selected inhibitors, we
generated dose-response curves by assessing cell viability
and calculating IC50 values for A375 cells: parental and
2 corresponding resistant derivatives (labeled -XP when
resistant to Vemurafenib and -GP when resistant to
Dabrafenib [16]) (Additional files 2 and 3: Figure S1 and
Table 1). To consolidate the data obtained in A375 cells,
we further tested 20 of the chosen inhibitors in IGR37
and 501Mel cells (Fig. 3a and Additional file 4: Figure S2).
From these results, 14 inhibitors were selected based
on their reproducibility, potency, and the quality of the
curves obtained: we chose drugs that either potently
inhibited proliferation in all 3 cell lines (Rigosertib,
MK-1775, AZD7762) or that targeted pathways not dir-
ectly linked to the MAPK pathway (IMD 0354 targeting
IKK, or PIK-75 targeting PI3K and DNA-PK). Only
drugs that presented acceptable dose response curves
with IC50 values well below 1 μM were further analyzed.
Overall, 8 inhibitors of kinases involved in cell cycle
regulation (targeting cyclin-dependent kinases (CDKs),
Aurora kinases (Aurks), Polo-like kinases (Plks), check-
point kinases (Chks)), along with 6 inhibitors targeting
different signaling pathways (see compounds marked in
grey in Table 1) showed best results.
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Assessment of combinatorial effects of selected kinase
inhibitors with BRAF inhibitors
Six of the 14 selected inhibitors (Rigosertib, Flavopiridol
HCl, AT7519, KX2–391, IMD0354 and Ponatinib) did
not act synergistically with the BRAF inhibitors (data
not shown). For the remaining 8 compounds, synergistic
effects with the BRAF inhibitors Vemurafenib and/or
Dabrafenib were scored in A375 cells (Fig. 2a and Add-
itional file 5: Figure S3). Synergism can be calculated
with different methods using effect-based strategies, like
the Bliss independence or the HSA (Highest Single
Agent) model or by dose-effect-based strategies, like the
Loewe additivity model [23]. Here we applied 2 different
tools to assess synergy: the Chou-Talalay method based
Table 1 Half-maximal inhibitory concentration value (IC50) for selected kinase inhibitors
Parental and BRAFi-resistant A375 melanoma cells underwent treatment for 72 h with 3-fold serial dilutions of each kinase inhibitor and cell viability was assessed
with the PrestoBlue Cell Viability assay. The IC50values (nM) were calculated as described in Methods. Values represent the mean of at least three biological
replicates. Highlighted in grey are inhibitors chosen for synergy studies and marked additionally with a hash (#) are inhibitors chosen for long-term testing. “n.e.”:
not efficient, inhibitors did not suppress growth below 50% in the tested concentration range. “-”: values could not be determined in GraphPad. SD: standard
deviation; -XP: cells resistant to Vemurafenib, -GP: cells resistant to Dabrafenib
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on Loewe additivity [18] and Synergyfinder, scoring syner-
gism using the 4 main models, HSA, Loewe, BLISS and
ZIP (Zero Interaction Potency) [20]. When the BRAF in-
hibitors Vemurafenib and Dabrafenib were combined with
drugs targeting the cell cycle like MK-1775 (Wee1i),
AZD7762 (Chki) and Danusertib (Aurki), clear synergistic
effects were observed as indicated by CI (combination
index) values < 1 calculated by the Chou-Talalay method
(Fig. 2a). CI values > 1 (marked in red) illustrate antagon-
ism, as seen for the lowest concentrations of MK-1775
and AZD7762. As expected, the combination of BRAF
and the MEK inhibitor AZD8330 also showed synergistic
effects at low concentrations (Fig. 2a, lower 2 panels). Fur-
ther combinations of inhibitors with synergistic effects are
shown in Additional file 5: Figure S3A. Interestingly
CHIR-124 (Chki), Volasertib (Plki) and PIK-75 (PI3Ki)
had synergistic effects only with Dabrafenib. Vemurafenib
showed synergism when combined with TAE226 (FAKi).
Additional file 5: Figure S3B confirms the synergistic com-
binations observed with the Chou-Talalay method, using
Synergyfinder, another tool for drug combination analysis:
red regions with synergy scores > 1 indicate synergism
(the regions of highest synergy are marked by a white
frame), whereas the green regions indicate antagonism.
Concentrations of drugs determining the regions of
highest synergy were generally in the lower ranges, further
strengthening their role as potential drug combination
partners.
To confirm the inhibition of Wee1 kinase by MK-1775,
Tyr15 phosphorylation levels of CDK1 (P-cdc2) were
tested [24] while specificity of the Chk1 inhibitor
AZD7762 was assessed by measuring induced phosphoryl-
ation of Chk1 [25, 26] (Additional file 6: Figure S4a). Both
inhibitors performed with the expected level of specificity.
The inhibition of Erk phosphorylation by Vemurafenib
was confirmed as observed before [17] and the FAKi
TAE226 worked by blocking P-Akt levels as expected [27].
Taken together, we identified 8 kinase inhibitors which
had synergistic effects on cell growth when combined
with Vemurafenib and/or Dabrafenib.
Combinatorial effects of cell cycle checkpoint inhibitors
The combination of Wee1 and Chk inhibitors both target-
ing key enzymes of cell cycle control can kill melanoma
cells independent of their BRAF mutation status [28, 29].
Here, both types of cell cycle inhibitors (AZD7762 and
CHIR-124 (Chki) and MK-1775 (Wee1i)) acted synergis-
tically with the BRAF inhibitors (Fig. 2a, Additional file 5:
Figure S3B). Therefore, we investigated whether a com-
bination of these drugs would also be effective in BRAF
inhibitor-resistant cells, as this would be of high clinical
relevance. Indeed, when the Wee1 inhibitor MK-1775 was
combined with the Chk inhibitors AZD7762 or
CHIR-124, highly synergistic effects were scored at the
concentrations tested (Fig. 2b) both for the sensitive but
importantly also for the BRAFi-resistant A375 cells (-XP:
resistant to Vemurafenib, -GP: resistant to Dabrafenib).
The same results were obtained with Chou-Talalay ana-
lysis, which indicated very low CI values (Additional file 7:
Figure S5A), and only at the lowest concentrations
CHIR-124 and MK-1775 lost their synergistic effects.
Fig. 1 Study outline of kinase inhibitor screening. Three BRAF mutated
melanoma cell lines, A375, IGR37 and 501Mel (each one in its parental
(P), Vemurafenib (XP)- and Dabrafenib (GP)-resistant form) were treated
with 2 concentrations (1 and 10 μM) of 274 different kinase inhibitors.
40 promising candidates were further characterized in dose-response
assays, which led to the identification of 14 compounds that were
used in combination treatments where synergism was assessed. Short-
and long-term effects of combinations with 8 successful drugs were
analyzed: Danusertib (Aurora kinase, FGFR, Bcr-Abl, c-RET, Src inhibitor),
MK-1775 (Wee1 inhibitor), AZD7762 (Chk inhibitor), AZD8330 (MEK
inhibitor), CHIR-124 (Chk inhibitor), Volasertib (Plk inhibitor), PIK-75
(PI3K, DNA-PK inhibitor), TAE226 (FAK inhibitor). BRAFi: BRAF inhibitor,
Vemurafenib or Dabrafenib
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Fig. 2 (See legend on next page.)
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MK-1775-driven Wee1 inhibition in parental and re-
sistant A375 cells reduced levels of inhibitory CDK1
(cdc2) phosphorylation, and this effect was enhanced by
the Chki AZD7762 (Fig. 3c). Vice versa, when cells were
treated with AZD7762, we observed increased levels of
inhibitory Ser317 phosphorylation in Chk1, which were
even more pronounced when Wee1 was inhibited in
parallel (Fig. 3c). Similar effects were also observed in
primary melanoma cells derived from a patient’s muscle
metastasis (M45) (Additional file 6: Figure S4C).
To further consolidate these observations, the same
treatments (MK-1775 combined with AZD7762) were
applied to 2 additional melanoma cell lines, both sensi-
tive and resistant to BRAF inhibitors, namely IGR37 and
501Mel, with identical results (Fig. 3a, Additional file 7:
Figure S5B). An intrinsically resistant cell line to BRAFi,
IGR39, was also tested and again we observed synergistic
killing effects of the MK-1775/AZD7762 combination
(Additional file 7: Figure S5C).
Next, we investigated if the combination of Wee1 and
Chk inhibitors induces apoptosis rather than slowing
down proliferation of parental and resistant A375 cells
and of the primary M45 melanoma cells (Fig. 3b and c,
Additional file 6: Figure S4). While single treatments
with 400 or 800 nM Wee1 inhibitor (MK-1775) and 400
nM Chk inhibitor (AZD7762) (blue bars) increased
apoptosis rates (measured by caspase-3 activity) up to
only 20%, the combined application of both drugs (green
bars) induced very high apoptosis levels similar to the
Etoposide treatment (positive control) in parental and
Dabrafenib-resistant cells, with less pronounced re-
sponses in Vemurafenib-resistant cells (Fig. 3b). Increas-
ing the concentration of MK-1775 (800 nM) in the
combination treatment did not enhance the effect fur-
ther (light green bars). In general, A375 cells resistant to
Dabrafenib (A375-GP) were more sensitive to apoptosis
induction, either by the control treatment (Etoposide) or
by the kinase inhibitors. Comparable results could also
be detected in the M45 primary cells (Additional file 6:
Figure S4B). Cleavage of PARP, another indicator for
apoptosis, was also induced by treatment with either
AZD7762, MK-1775 and even more so with their com-
bination (Fig. 3c, Additional file 6: Figure S4C). More-
over, we tested the effects of candidate drugs on normal/
healthy cells present in and around the tumor, namely
melanocytes (NHEM) and fibroblasts (NHDF). As ex-
pected, the very specific BRAF inhibitors Vemurafenib
and Dabrafenib did not have any effect on the healthy
counterpart cells, alone or in combination with the dif-
ferent other inhibitors (Fig. 4 and Additional file 8: Fig-
ure S6). The Wee1 inhibitor MK-1775 and the Chki
AZD7762 had very modest effects on healthy fibroblasts
and melanocytes at lower concentrations, which is in
line with results observed by Magnussen and colleagues
[30]. When both drugs were combined, we observed
nearly no caspase-3 activation and no PARP cleavage at
all (Additional file 6: Figure S4).
The beneficial effects of combining Chk and Wee1 in-
hibitors have been demonstrated in BRAF mutant and
wild-type melanoma cells, as well as in other human
tumor cell lines [28, 29, 31, 32]. Here, we confirm these
observations and additionally, our study highlights the ef-
ficacy of this combination especially on melanoma cells
rather than healthy surrounding cells, and also import-
antly in the context of acquired and intrinsic BRAF inhibi-
tor resistance. To assess the effect of Wee1 and Chk
inhibition in vivo, we tested MK-1775, AZD7762 and the
combination of both in mice injected subcutaneously with
parental sensitive A375 cells or Vemurafenib-resistant
A375-XP cells (Fig. 5). The combined inhibition of Wee1
and Chk stopped tumor growth in resistant and even
more so in sensitive tumors, supporting the clinical rele-
vance of our findings. Additionally, mice did not lose
weight nor did they show any obvious side effects during
treatment, altogether indicating no major toxicity issues.
Long-term treatments
As patients are generally treated over longer periods of
time, long-term in vitro studies are necessary to finally
conclude on drug effects. The often used 48-72 h assays
(See figure on previous page.)
Fig. 2 Combinations of different kinase inhibitors show synergistic effects in drug-sensitive and –resistant melanoma cells. a A375 cells were
treated for 72 h with BRAF inhibitors Vemurafenib or Dabrafenib alone or in combination with MK-1775 (Wee1i), AZD7762 (Chki), Danusertib
(Aurki) or AZD8330 (MEKi) and cell viability was assessed. A dose-effect analysis of the drug combinations to determine synergism/antagonism
based on the Chou-Talalay method was performed using the Compusyn software. Combination index (CI) values shown above the bars were
mostly < 1 indicating a synergistic effect of both drugs at the specific concentrations. CI values > 1 (marked in red), indicate antagonism; white
bars show BRAFi treatment alone, grey bars show the tested kinase inhibitor alone and black bars show the combined drugs. Red arrows
pinpoint the most effective combinations. One representative experiment of at least 3 is shown. b Chki and Wee1i act synergistically on parental
and BRAFi-resistant A375 cells. Parental and resistant A375 cells (-XP: Vemurafenib-resistant; -GP: Dabrafenib-resistant) were treated for 72 h with
the indicated concentrations of 2 Chki (AZD7762 or CHIR-124) and a Wee1i (MK-1775) and cell viability was assessed. Synergy scores were
calculated using the Synergyfinder software. ZIP Synergy scores > 0 indicate synergism (red regions) and scores < 0 indicate antagonism (green
regions). Concentrations marked with green boxes on the x and y-axis indicate the concentrations encompassing the region of highest synergy
(indicated by the white rectangle). The value in the white box represents the averaged synergy score for the region of highest synergy. One
representative experiment of at least 4 is shown
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are not adequate to exclude that resistance will eventu-
ally occur, even with a combination of drugs that are
synergistic using the above shown conditions.
Based on the promising synergistic effects (Fig. 2,
Additional file 5: Figure S3 and Additional file 7:
Figure S5), the following 8 kinase inhibitors were se-
lected for further characterization in long-term exper-
iments: Danusertib (Aurora kinase, FGFR, Bcr-Abl,
c-RET, Src inhibitor), MK-1775 (Wee1i), AZD7762
(Chki), CHIR-124 (Chki), Volasertib (Plki), PIK-75
(PI3K, DNA-PK inhibitor) and TAE226 (FAKi) (see
Table 1, marked in grey with #). We generated paren-
tal and resistant A375 cells stably expressing iRFP
(near-infrared fluorescent protein) to be able to moni-
tor effects of the inhibitors over time. iRFP fluores-
cence was quantified on a LICOR imaging system,
allowing for continuous proliferation measurements
following single kinase inhibitor or combined treat-
ments. After 11 weeks in the presence of drugs, cells
were fed for another 3 weeks with regular medium, in
order to evaluate if combination treatments had killed
all cells or if residual melanoma cells would resume
their growth once the drugs were removed.
In a first set of treatments, different kinase inhibitors
were combined with Dabrafenib or Vemurafenib (data
not shown) in parental A375 cells. Figure 6a clearly indi-
cates that until day 76 (11 weeks, after this timepoint the
drugs were removed) a combination of Dabrafenib with
AZD7762 (Chki) or MK-1775 (Wee1i) was able to stop
cell growth. As expected, cells had become resistant to
the single treatments and continued to proliferate,
except in presence of 300 nM CHIR-124 (another Chki)
which killed most of the cells, opposed to 150 nM of this
drug, which was not sufficient to prevent cells to grow
back even in the presence of both drugs (with Dabrafe-
nib, data not shown). This highlights the importance of
treatment with adequate drug concentrations for preven-
tion of tumor recurrence. PIK-75 together with Dabrafe-
nib was also efficient in suppressing growth over
extended periods of time, as compared to the single
treatments. Regarding Danusertib, the results were in-
consistent, with only 1 out of 3 wells showing resistant
cells in the single treatment. A concentration of 40 nM
Volasertib (Plki) (and also 20 nM, data not shown) killed
all cells.
Notably, removal of most drugs from the cell medium
after day 76 (marked by the red arrow) allowed for
remaining cells to grow back even in the combined
treatments. By day 97 (after 20 days without drugs) cells
had re-grown for most treatments. The combined inhib-
ition of BRAF and Plk (by Volasertib) marked an excep-
tion where hardly any surviving cells were detected at
day 97, while cells treated with Volasertib alone had
started to grow back. Identical results were obtained
A
B
C
Fig. 3 Effects of checkpoint inhibitors MK-1775 (Wee1i) and AZD7762
(Chki) on parental and resistant melanoma cells. a Dose-response
curves and IC50 values (in nM) of MK-1775 and AZD7762 in A375,
IGR37 and 501Mel melanoma cells. Response to 3-fold serial dilutions
of each kinase inhibitor was assessed 72 h after treatment. The IC50
values (nM) were calculated as indicated in Methods. Values represent
the mean of at least three biological replicates. SD: standard deviation;
XP: cells resistant to Vemurafenib, GP: cells resistant to Dabrafenib. b
The combination of MK-1775 and AZD7762 efficiently induces
apoptosis in parental and BRAFi-resistant A375 cells. Cells were treated
for 72 h with the indicated concentrations of MK-1775 (Wee1i) or
AZD7762 (Chki) or a combination thereof. Etoposide (Eto) treatment
was used as positive apoptosis control. Resulting caspase-3 activity was
normalized to the untreated control. Error bars represent the standard
deviation of four biological replicates. Statistical significance was
determined with one-way repeated measures ANOVA followed by
Dunnett’s post-test. *p > 0.05, **p > 0.01, ***p > 0.001. c Western blot
analysis of A375, A375-XP and A375-GP cells after treatment for 3 or
24 h with indicated amounts of drugs. P-cdc2 (CDK1), cdc2 (CDK1), p-
Chk1 and Chk1 were detected after 3 h drug treatment, while PARP
cleavage was detected after 24 h treatment. Vinculin and α-tubulin
were used as loading controls. AZD: AZD7762, MK: MK-1775
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with 20 nM Volasertib (data not shown). Taken together,
treatments combining BRAF inhibition with Chk
(AZD7762, CHIR-124), Wee1 (MK-1775) or Plk (Vola-
sertib) inhibition led to a more efficient response than
with single treatments, although cells partially re-grew
after removal of the drugs. Overall, these findings sug-
gest that such combined treatments with optimized
concentrations and treatment duration could have more
durable clinical effects for advanced-stage melanoma pa-
tients. Ultimately, ideal concentrations and durations of
single or combined drugs and their treatments have to
be established in clinical trials.
Finally, we combined the most promising Chk and
Wee1 inhibitors AZD7762 and MK-1775, since they
Fig. 4 Dose-response studies of selected kinase inhibitors in non-cancer NHEM and NHDF cells. a Response to 3-fold serial dilutions of each
kinase inhibitor was assessed 72 h after treatment by measuring cell viability. b The table indicates the half-maximal inhibitory concentrations
(IC50) for the selected inhibitors. The IC50 values (nM) were calculated as indicated in Methods. Values represent the mean of at least three
biological replicates. “n.e.”: not efficient: inhibitors did not suppress growth below 50% in the tested concentration range. “-”: values could not be
determined in GraphPad. NHEM: normal human epidermal melanocytes; NHDF: normal human dermal fibroblasts
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showed high degrees of synergism in parental but also in
several BRAF inhibitor-resistant melanoma cell lines,
over longer periods of time. In parental A375 cells, a
clear advantage of combinations, with no cell growth
visible until day76 (with low and higher concentrations
of MK-1775, Fig. 6b) was observed. After removal of
drugs, at least 1 out of 3 wells of parental A375 cells
showed few surviving cells.
Interestingly, cells resistant against either Vemurafenib
or Dabrafenib, reacted differently to secondary drugs
under short- and long-term exposure (Figs. 3 and 6).
These findings argue for personalized 2nd line treatments,
which may vary depending on the administered 1st line
drug. Furthermore, long-term experiments illustrate that
drugs (even in combination) that seem to act synergistic-
ally in 72 h assays can still induce resistance over longer
exposure times, making them less likely to work in pa-
tients where drugs are usually administered over many
months. Additionally, we could show that the combin-
ation of the Chk and Wee1 inhibitors is promising when
treating parental, but also BRAF inhibitor resistant cells.
Discussion
Even though melanoma has been the posterchild when it
comes to advances in cancer treatment over the last few
years, there is still a long way to go until a larger
A
B
Fig. 5 Combination treatments efficiently reduce growth of A375-derived melanoma tumors in mice. NSG mice were injected subcutaneously
with A375 cells (a) (n = 10 mice/group) and A375-XP cells (b) (n = 5 mice/group). After 14 days, when tumors were approximately 150mm3, treatment was
initiated (indicated by an arrow) by daily gavage (MK-1775, Wee1 inhibitor) or daily intraperitoneal injection (AZD7762, Chk inhibitor) or a combination of
both inhibitors, for 8 consecutive days. Tumor growth was evaluated every second day and weights of extracted tumors were measured at end-point. The
tumor volumes are presented relative to the tumor volume at the day before initiation of treatment. Data are presented as means ± SEM, *p < 0.05, **p <
0.01 ***p < 0.001 compared to vehicle-treated tumors. Comparison of tumor volumes was performed with a two-way ANOVA between groups followed
by post-hoc Tukey’s multiple comparison tests
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percentage of advanced stage patients can expect a much
prolonged progression-free survival (PFS) or even to be
cured. Largely, melanoma patients fall into 2 groups:
BRAF wt and BRAF mutant, for which efficient targeted
therapies exist. Combined BRAF and MEK inhibition
have increased median PFS to 9–11 months [7], but
could have much better clinical outcomes if it was not
for the inevitable emergence of drug resistance. For
BRAF wt (~ 50%) and also for drug-resistant patients, a
new treatment option has become available in recent
years: immunotherapy with PD-1 (Programmed cell
death protein 1), PD-L1 (Programmed death-ligand 1)
and CTLA4 (cytotoxic T-lymphocyte associated protein
4) immune checkpoint inhibitors.
Kinases represent one of the largest groups of drug-
gable proteins: the 518 kinases encoded within the hu-
man genome are involved in basically all signaling
pathways and their functions are often aberrantly regu-
lated not only in cancer but also in immunological,
metabolic or degenerative disorders. As a consequence,
many successful kinase inhibitors have been developed
for the clinical treatment of several cancers and other
Fig. 6 Long-term treatment of A375 cells with single inhibitors or synergistic drug combinations. a Parental A375 cells expressing iRFP were
treated for up to 76 days (11 weeks) with the BRAF inhibitor Dabrafenib alone or in combination with selected kinase inhibitors. b Parental and
BRAFi-resistant A375 cells (-XP: Vemurafenib-resistant; -GP: Dabrafenib-resistant) expressing iRFP were long-term treated with a Wee1i (MK-1775)
alone or in combination with a Chki (AZD7762) at the indicated concentrations. Cell growth was monitored over time by quantifying fluorescence on
a LICOR Odyssey Imaging system (at least 3 wells per treatment). Red circles indicate wells with saturation, where no fluorescence quantification in the
linear range was possible. Red arrows mark the timepoint (after day 76) when drugs were removed from the medium. The combined treatment was
set to 1. Dabra: Dabrafenib
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diseases (e.g. Imatinib (Gleevec), Crizotinib, Tofacitinib,
Ruxolitinib). Currently, 43 inhibitors have FDA approval
(www.brimr.org/PKI/PKIs.htm) [33]. The biggest part of
these drugs are ATP competitive inhibitors, targeting the
ATP pocket of the kinase either in its active (Type I in-
hibitors) or inactive (Type II inhibitors) state. Type III
and IV inhibitors bind to pockets that are specific for
each kinase, making them much more selective. To date,
only 3 inhibitors (all of them MEK inhibitors: Trameti-
nib, Cobimetinib and Binimetinib) are of the highly se-
lective Type III (www.brimr.org/PKI/PKIs.htm) [33]. The
ATP-binding site is highly conserved among all kinases,
and for this reason the so called “poly-pharmacology ef-
fect” (inhibitors targeting more than one protein) is
often observed with Type I and II inhibitors. These
off-target effects can have detrimental consequences (se-
vere side effects of treatment) for patients, however they
could also be exploited for drug repurposing. Recent
studies have profiled kinase inhibitors across the kinome
[33–36] to get further insights into their target specifi-
city and potency, their kinase and non-kinase off-target
effects [37].
In order to find new combinations of kinase inhibitors
to treat BRAFi-resistant melanoma, delay or avoid devel-
opment of resistance, we have screened a 274-kinase
inhibitor library in BRAF mutant melanoma cell lines,
sensitive and resistant to different BRAF inhibitors. Not
surprisingly, the most potent responses were seen with
inhibitors targeting cell cycle regulators, which have
strong effects on cell growth, already when given on
their own [14, 38]. Important players include the cyclin-
dependent kinases (CDKs), the DNA damage checkpoint
kinases Chk1, Chk2 and Wee1, and the mitotic spindle
assembly checkpoint Polo-like kinases (Plk) as well as
Aurora kinases (Aurk) (see Fig. 7). Numerous inhibitors
targeting these kinases are available, with some already in
clinical use (e.g. the highly specific CDK4 and − 6 inhibi-
tors Palbociclib and Ribociclib for breast cancer patients).
Different rationales speak for targeting cell cycle proteins:
(i) Aberrantly regulated CDKs (in melanoma 75 to
90% of tumors show mutations in the p16INK4A-
cyclinD-CDK4/6-Rb pathway) (reviewed in [39])
allow for uncontrolled tumor growth overriding
crucially important checkpoints, making these ki-
nases very prominent drug targets. Many CDK in-
hibitors are currently in clinical trials for melanoma
treatment [39, 40].
(ii) Aiming at checkpoint kinases like Chk1 or Wee1
that normally halt cell cycle progression to allow for
DNA damage repair would prevent these arrests and
drive cell proliferation, despite the accumulation of
DNA damage, possibly leading to apoptosis during
mitosis (“mitotic catastrophe”) [41]. Replicative stress
(RS), which is the interruption of replication fork
progression and/or DNA synthesis during replication,
can be induced by depletion of nucleotide pools,
reactive oxygen species (ROS), oncogenic signaling
and tumor suppressor inactivation, all present in
melanoma cells. Considerable RS, an uncommon
feature of normal cells, can lead to apoptotic and
non-apoptotic cell death [13, 42]. RS is also a strong
activator of Chk1 and Wee1, again making these
checkpoint proteins interesting drug candidates. So
far, the Wee1 inhibitor MK-1775 (AZD-1775) is be-
ing tested in clinical studies, alone and in combin-
ation with multiple other compounds. At present
(July 2018) 50 studies for MK-1775 were recorded in
ClinicalTrials.gov, only 1 of them including melan-
oma patients. Also several Chk1 inhibitors have been
Fig. 7 Pathways affected by the combined selected kinase inhibitors in BRAF mutant melanoma cells. Scheme summarizing the effects of cell
cycle-influencing proteins targeted by the identified kinase inhibitors (black boxes). The pathway on the right (grey background) represents
mitogenic factor-induced or mutated BRAF-induced entry into the cell cycle, while the left box (blue background) depicts players involved in
progression through the different checkpoints and phases of the cell cycle. cdc25: cell division cycle 25
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tested, among them AZD7762, that had to be discon-
tinued due to high cardiac toxicity [43].
(iii)Like anti-mitotic drugs (e.g. Taxol), the therapeutic
targeting of the mitotic Polo-like (Plk) and Aurora ki-
nases, overexpressed in many cancer types (reviewed
in [14, 44]), can induce mitotic cell arrest and cell
death. Volasertib and Rigosertib targeting Plk1 are 2
promising inhibitors inducing cell cycle arrest and
apoptosis, which are in clinical trials for different
cancer entities, except melanoma. Likewise, various
inhibitors of the A and B members of the Aurora
kinase family (e.g. Alisertib, Danusertib) are in clinical
studies [14].
One of the goals of our study was to find novel combin-
ation treatments with BRAF inhibitors that would act syn-
ergistically and could prevent or overcome resistance. We
have identified several drugs that target the DNA damage
checkpoint kinases Chk1/2 and Wee1 (namely AZD7762,
CHIR-124 and MK-1775, respectively) and that work syn-
ergistically with BRAF inhibitors, as quantified through an
effect based (Synergyfinder) and a dose-effect based
(Chou-Talalay) methodology (Fig. 2a and Additional file 5:
Figure S3). Interestingly, Wee1 kinase was identified as a
downstream target of BRAF V600E [45] and its expression
was found to be upregulated in melanoma as compared to
benign nevi [30]. This combined inhibition of mutated
BRAF and Wee1 is a very good example of vertical path-
way inhibition where 2 players within the same oncogenic
pathway are targeted, making the treatment more effica-
cious and lowering the chances of resistance development.
In our hands, even after 11 weeks of combined treatment
with Dabrafenib and MK-1775, cells had not become
resistant (Fig. 6a). A few surviving cells were able to grow
back after the drugs had been removed from the medium,
indicating the need for further adjustments of initial drug
concentrations and duration of treatment. The same
observations were made when BRAF inhibitors were
combined with the Chk inhibitors AZD7762 and
CHIR-124.
Targeting the Aurora kinases A and B with Danusertib
in combination with the BRAF inhibitors Vemurafenib
and Dabrafenib synergistically killed A375 melanoma
cells (Fig. 2a). This pan-Aurora kinase inhibitor also in-
duced apoptosis and inhibited migration of several other
melanoma cell lines [46].
Volasertib, an inhibitor of the mitotic kinase Plk1, had
strong synergistic effects with the BRAF inhibitor Dabra-
fenib (Additional file 5: Figure S3A). Long-term experi-
ments showed that 40 nM of Volasertib on its own was
enough to keep cells in check, but when inhibitors were
removed from the medium after 11 weeks, only the com-
bined treatment with Dabrafenib and Volasertib was able
to prevent recurrence of cell growth. Volasertib (BI
6727) had been shown to delay growth of melanoma tu-
mors and to cause regression by inducing apoptosis in
vivo [47] and, importantly, it showed synergistic antitu-
mor effects together with the MEK inhibitor Trametinib
in NRAS mutant melanoma [48]. This inhibitor has been
studied extensively in over 25 clinical trials, but has not
received FDA approval yet.
Furthermore, we have also observed synergistic effects
of horizontal inhibition of the cross-talking pathways,
PI3K/Akt and MAPK (Additional file 5: Figure S3A). A
draw-back of this strategy is the appearance of
dose-limiting toxicities, but many combinations are cur-
rently tested in clinical trials (reviewed in [49]).
Another interesting observation is the synergistic com-
bination of Vemurafenib with the FAK inhibitor TAE226
(Additional file 5: Figure S3). FAK was recently de-
scribed to be involved in the emergence of dedifferen-
tiated, BRAFi-adapted cells and its inhibition increased
killing effects of BRAF and MEK inhibitors [50]. Using a
computational approach, Gayvert and colleagues discov-
ered a synergistic interaction between Vemurafenib and
FAK inhibitor 14 [51]. Very importantly, the tumor
microenvironment, namely melanoma associated
fibroblasts, were activated by BRAF inhibition inducing
FAK-dependent melanoma survival and a combination
of Vemurafenib with a FAK inhibitor lead to tumor
regression in mouse allografts and patient-derived xeno-
grafts [52]. Notably, all of the above-mentioned inhibi-
tors that had synergistic effects with BRAF inhibitors
also very efficiently (low IC50 values) killed BRAFi-resist-
ant melanoma cells (A375, IGR37, 501Mel) on their own
(See Table 1, Fig. 3a, Additional file 3: Figure S1 and
Additional file 4: Figure S2).
The combined inhibition of Wee1 and Chk1/2 has
shown very promising effects when applied to other can-
cer cells but also melanoma cells (reviewed in [13]).
Since we were interested in finding drug combinations
that would also kill BRAFi-resistant melanoma cells, we
extensively studied these drug pairs (AZD7762 (Chki)
and MK-1775 (Wee1i) or CHIR124 (Chki) and MK-1775
(Wee1i)) in drug-naïve and -resistant melanoma cell
lines (Figs. 2b, 5 and Additional file 7: Figure S5). We
could clearly show that combined inhibition of Chk1/2
and Wee1 synergistically killed BRAFi-resistant cells and
more importantly, reduced tumor growth by up to 50%
in an in vivo melanoma mouse model. In long-term
treatments over 11 weeks especially the BRAFi-resistant
A375 cells (A375-XP and –GP) showed no or very little
regrowth of cells when drugs were removed from the
medium (Fig. 6b). These results indicate that the Wee1/
Chk1/2 inhibition could be an encouraging therapeutic
option for BRAFi-resistant melanoma patients.
Until entirely new treatment regimens such as more
efficient immunotherapies, combinatorial inhibition with
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drugs targeting histone deacetylases (HDACs) or indu-
cing apoptosis (reviewed in [15]) or immunotherapies
together with oncolytic viruses [53, 54] as well as per-
sonalized cocktails of combined treatments come into
practice, more efficient combinations of available and
FDA-approved kinase inhibitors could improve
progression-free survival of melanoma patients, who are
not eligible to BRAF inhibition or have become resistant
to this treatment. For those patients (at least 50%) other
kinase inhibitor combinations, either given as targeted
therapy alone or before or after immunotherapy, could
become the treatment of choice.
Conclusion
Taken together, we have identified and characterized syn-
ergistic kinase inhibitor treatments targeting the MAPK
pathway and the cell cycle that could be promising alter-
natives for drug-resistant melanoma patients or wild-type
BRAF patients. Interestingly, different drug combinations
were effective depending on which one of two standard
BRAF inhibitors was used in 1st line therapy. Finally, we
show that fine-tuned drug concentrations and optimized
treatment durations are necessary to achieve long lasting
effects without rapid emergence of resistance.
Additional files
Additional file 1: Table S1. Kinase inhibitor library screening. A
commercial kinase inhibitor library of 274 compounds was tested on 3
different BRAF mutant melanoma cell lines, A375, IGR37 and 501Mel.
Each cell line was treated in its sensitive form (parental), and also as 2
resistant derivatives, which were made resistant to either Vemurafenib
(XP) or Dabrafenib (GP). Drugs were added at 2 different concentrations,
1 and 10 μM, for 72 h and cell viability was assessed using the PrestoBlue
Cell Viability assay. Results are depicted as % viability compared to
untreated cells. Each cell line was analyzed at least in duplicate. Inhibitors
that were further analyzed and characterized in more detail are marked
in red. (XLSX 95 kb)
Additional file 2: Table S2. Mutation status of genes related to this
study. Data are based on own sequencing experiments (WES and Sanger
sequencing), online available data from the “COSMIC cell lines project”
(https://cancer.sanger.ac.uk/cell_lines) and on literature (Halaban et al.,
Pigm Cell Mel Res, 2010). Synonymous mutations or mutations in non-
coding sequences were not taken into account here. wt: no mutation de-
tected; ni: no information available. Genomic profiles (exome sequencing)
of the cell lines (A375, -XP and –GP, IGR37, -XP and –GP and IGR39) are
available upon request. (PDF 63 kb)
Additional file 3: Figure S1. Dose-response curves of selected kinase
inhibitors in parental and BRAFi-resistant A375 cells. Response to 3-fold
serial dilutions of each kinase inhibitor was assessed 72 h after treatment
by measuring cell viability. Interesting candidates further tested in com-
bination treatments in A375 cells are highlighted by a red frame (see also
Table 1). One representative curve of at least 3 biological replicates is
depicted here. _XP: cells resistant to Vemurafenib, _GP: cells resistant to
Dabrafenib. (PDF 1030 kb)
Additional file 4: Figure S2. Dose-response curves of selected kinase
inhibitors in parental and BRAFi-resistant IGR37 and 501Mel cells. Re-
sponse to 3-fold serial dilutions of each kinase inhibitor was assessed 72
h after treatment by measuring cell viability in IGR37 (A) and 501Mel (B)
cells. The values depicted in the different graphs indicate the half-
maximal inhibitory concentrations (IC50) of inhibitors for which IC50 values
could be determined (as explained in Methods). Values represent the
mean of at least three biological replicates; one representative curve of at
least 3 biological replicates is depicted. _XP: cells resistant to Vemurafenib
(red), _GP: cells resistant to Dabrafenib (green). (PDF 304 kb)
Additional file 5: Figure S3. BRAF inhibitors in combination with
selected kinase inhibitors synergistically inhibit proliferation of A375
melanoma cells. A) A375 cells were treated for 72 h with Dabrafenib
alone or in combination with CHIR-124 (Chki), Volasertib (Plki) or PIK-75
(PI3Ki, DNA-PKi), or with Vemurafenib alone or combined with TAE226
(FAKi) and cell viability was determined . A dose-effect analysis of the
drug combination based on the Chou-Talalay method was performed
using the Compusyn software. CI values shown above the bars were
mostly < 1 indicating a synergistic effect of both drugs at the specific
concentrations. CI values marked in red are > 1, indicating antagonism.
White bars show BRAFi treatment alone, grey bars show the tested kinase
inhibitor alone and black bars represent the combined drugs. One repre-
sentative experiment of at least 3 is shown. B) A375 cells were treated for
72 h with the indicated concentrations of MK-1775 (Wee1i), AZD7762
(Chki), Danusertib (Aurora kinase i) and TAE226 (FAKi) or CHIR-124 (Chki)
in combination with either Vemurafenib (upper panel) or Dabrafenib
(lower panel) and cell viability was assessed. The synergy score for each
combination was calculated using the Synergyfinder software. Concentra-
tions marked with green boxes on the x and y-axis indicate the concen-
trations encompassing the region of highest synergy (indicated by the
white rectangle). The value in the white box represents the averaged
score for the region of highest synergy. One representative experiment of
at least three biological replicates is shown. (PDF 194 kb)
Additional file 6: Figure S4. Western blot analysis for selected drug
treatments and apoptosis assays in healthy and melanoma cells. A)
Western Blot analysis of A375, A375-XP and A375-GP cells treated with
the BRAFi Vemurafenib (PLX), Chki AZD7762 (AZD), Wee1i MK-1775 (MK),
FAKi TAE226 (TAE) or combinations thereof. Cells were treated for 3 h
with indicated concentrations of inhibitors. Actin staining was used as
loading control. B) The combination of MK-1775 and AZD7762 efficiently
induced apoptosis in primary melanoma cells (M45), but not so much in
healthy cells. Cells were treated for 72 h with the indicated concentra-
tions of MK-1775 (Wee1i) or AZD7762 (Chki) or a combination thereof.
Etoposide (Eto) treatment was used as positive apoptosis control. Result-
ing caspase-3 activity was normalized to the untreated control. 1 repre-
sentative experiment out of 3 is shown. C) Western blot analysis of
NHEM, NHDF and M45 primary melanoma cells after treatment for 3 or
24 h with indicated amounts of drugs. P-cdc2 (CDK1), cdc2 (CDK1), p-
Chk1 and Chk1 were detected after 3 h drug treatment, while PARP
cleavage was detected after 24 h treatment. Vinculin and α-tubulin were
used as loading controls. AZD: AZD7762, MK: MK-1775; NHEM. Normal hu-
man epidermal melanocytes, NHDF: normal human dermal fibroblasts.
(PDF 306 kb)
Additional file 7: Figure S5. Chou-Talalay analysis: A combination of
Wee1 and Chk inhibitors synergistically inhibits proliferation of sensitive
and resistant melanoma cells. A) Parental and BRAFi-resistant A375 cells
were treated with MK-1775 (Wee1i) alone or in combination with either
AZD7762 (left panel) or CHIR-124 (right panel) (both Chki). B) Parental
and BRAFi-resistant IGR37 (left panel), 501Mel (right panel) cells and C) in-
trinsically resistant IGR39 cells were treated with MK-1775 (Wee1i) alone
or in combination with AZD7762 (Chki). After 72 h, cell viability was deter-
mined. A dose-effect analysis of the drug combination was performed
using the Compusyn software. CI values shown above the bars were
mostly < 1 indicating a synergistic effect of both drugs at the specific
concentrations. CI values marked in red are > 1, indicating antagonism.
White bars show Wee1i (MK-1775) treatment alone, grey bars show Chki
(AZD7762 or CHIR-124) treatment alone and black bars show the com-
bined drugs. Red arrows pinpoint the most effective combinations. One
representative experiment of at least 3 is shown here. A375/IGR37/
501Mel-XP: resistant to Vemurafenib; A375/IGR37/501Mel-GP: resistant to
Dabrafenib. (PDF 294 kb)
Additional file 8: Figure 6. Dose-response curves of selected kinase in-
hibitors in the presence or absence of BRAF inhibitors in healthy cells. A)
NHEM and B) NHDF cells were subjected to 3-fold serial dilutions of each
kinase inhibitor in the presence or absence of constant amounts of
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Vemurafenib (5 µM) or Dabrafenib (100 nM). Cell viability was assessed
72h after treatment by measuring cell viability. One representative curve
of at least 3 biological replicates is depicted. NHEM: normal human epi-
dermal melanocytes; NHDF: normal human dermal fibroblasts.
(PDF 238 kb)
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maximal inhibitor concentration; iRFP: Near-infrared fluorescent protein;
MAPK: Mitogen activated protein kinase; MEK: MAPK/Erk kinase;
NHDF: normal human dermal fibroblasts; NHEM: normal human epidermal
melanocytes; NRAS: neuroblastoma RAS viral oncogene homolog;
PFS: Progression-free survival; PI3K: Phosphoinositide 3-kinase; Plk: Polo-like
kinase; RS: Replicative stress; wt: wild-type; XP: Vemurafenib/PLX4032-resistant
pool; ZIP: Zero Interaction Potency
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